奥沙利铂
医学
成本效益
安慰剂
养生
卡培他滨
内科学
肿瘤科
癌症
结直肠癌
风险分析(工程)
替代医学
病理
作者
Shufei Lai,Shaohong Luo,Qingwen Huang,Shen Lin,Xiaoting Huang,Honglin Xue,Yi-Jun Cai,Xiongwei Xu,Xiuhua Weng
出处
期刊:Pharmacogenomics
[Future Medicine]
日期:2024-04-12
卷期号:: 1-9
标识
DOI:10.1080/14622416.2024.2344438
摘要
Aim: To estimate the cost–effectiveness of zolbetuximab plus capecitabine/oxaliplatin (CAPOX) in CLDN18.2-positive, HER2-negative, mG/GEJ adenocarcinoma from the perspective of Chinese payers. Materials & methods: A partitioned survival model was developed to assess the costs, quality-adjusted life years (QALYs) and incremental cost–effectiveness ratios (ICER) of zolbetuximab plus CAPOX versus placebo plus CAPOX. Sensitivity analyses were performed to test the robustness of model. Results: Zolbetuximab plus CAPOX gained an additional cost of $91,551 and an extra health benefit of 0.24 QALY over placebo plus CAPOX, producing an ICER of $388,186/QALY, which exceeded the willingness-to-pay threshold of $38,223/QALY. Sensitivity analysis shows that the model was generally robust. Conclusion: Zolbetuximab plus CAPOX would not be a cost-effective first-line treatment regimen in CLDN18.2-positive, HER2-negative, mG/GEJ adenocarcinoma in China.
科研通智能强力驱动
Strongly Powered by AbleSci AI